# Xeris Biopharma Holdings, Inc.: overview

XERS · Nasdaq · CIK 1867096 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xers.md) · [Financials](/companies/xers/financials.md) · [Filings](/companies/xers/filings.md) · [Insiders](/companies/xers/insiders.md)

Latest reported revenue: [$92.1m](/filings/0001867096-26-000065.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001867096-26-000065).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [54.3](/filings/0001867096-25-000159.md) | [60.1 d](/filings/0001867096-26-000016.md) | [60.1](/filings/0001867096-26-000030.md) | [71.5](/filings/0001867096-26-000065.md) | [74.4](/filings/0001867096-25-000159.md) | [85.8 d](/filings/0001867096-26-000016.md) | [83.1](/filings/0001867096-26-000030.md) | [92.1](/filings/0001867096-26-000065.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(23.8%)](/filings/0001867096-25-000159.md) | [2.8% d](/filings/0001867096-26-000016.md) | [(5.1%)](/filings/0001867096-26-000030.md) | [6.3%](/filings/0001867096-26-000065.md) | [9.0%](/filings/0001867096-25-000159.md) | [19.5% d](/filings/0001867096-26-000016.md) | [9.5%](/filings/0001867096-26-000030.md) | [5.6%](/filings/0001867096-26-000065.md) |
| Net margin | % | [(29.0%)](/filings/0001867096-25-000159.md) | [(8.5%) d](/filings/0001867096-26-000016.md) | [(15.3%)](/filings/0001867096-26-000065.md) | [(2.7%)](/filings/0001867096-26-000065.md) | [0.8%](/filings/0001867096-25-000159.md) | [12.9% d](/filings/0001867096-26-000016.md) | [2.7%](/filings/0001867096-26-000065.md) | [(33.8%)](/filings/0001867096-26-000065.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001867096-25-000159.md) | not reported | [(0.06)](/filings/0001867096-26-000030.md) | [(0.01)](/filings/0001867096-26-000065.md) | [0.00](/filings/0001867096-25-000159.md) | not reported | [0.01](/filings/0001867096-26-000030.md) | [(0.18)](/filings/0001867096-26-000065.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [49.6](/filings/0001867096-24-000031.md) | [110](/filings/0001867096-25-000039.md) | [164](/filings/0001867096-26-000016.md) | [203](/filings/0001867096-26-000016.md) | [292](/filings/0001867096-26-000016.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(232.2%)](/filings/0001867096-24-000031.md) | [(74.3%)](/filings/0001867096-25-000039.md) | [(26.8%)](/filings/0001867096-26-000016.md) | [(16.6%)](/filings/0001867096-26-000016.md) | [8.5%](/filings/0001867096-26-000016.md) |
| Net margin | % | [(247.5%)](/filings/0001867096-24-000031.md) | [(85.9%)](/filings/0001867096-25-000039.md) | [(38.0%)](/filings/0001867096-26-000016.md) | [(27.0%)](/filings/0001867096-26-000016.md) | [0.2%](/filings/0001867096-26-000016.md) |
| Diluted EPS | $ per share | [(1.55)](/filings/0001867096-24-000031.md) | [(0.70)](/filings/0001867096-25-000039.md) | [(0.45)](/filings/0001867096-26-000016.md) | [(0.37)](/filings/0001867096-26-000016.md) | [0.00](/filings/0001867096-26-000016.md) |
| Free cash flow | $m | [(96.6)](/filings/0001867096-24-000031.md) | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xers/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $115.0m | 14,525,539 |  | Added +1,579,754 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $61.8m | 7,804,758 |  | Added +15,947 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $58.1m | 7,340,229 |  | Added +359,347 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $38.2m | 4,821,566 |  | Added +163,392 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $37.4m | 4,718,183 |  | Added +427,554 |
| [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $34.7m | 4,385,141 |  | Added +1,468,543 |
| [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $23.0m | 2,908,981 |  | Reduced −322,719 |
| [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $22.9m | 2,893,749 |  | Reduced −1,220,676 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $20.8m | 2,626,208 |  | Reduced −39,400 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $18.7m | 2,365,103 |  | Added +193,749 |

## Recent filings

[All 335 filings](/companies/xers/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-14 | 07:08 ET | [8-K](/filings/0001867096-26-000091.md) | 8.01 Other events | 0001867096-26-000091 |
| 2026-09-09 | 08:33 ET | [8-K](/filings/0001867096-26-000077.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001867096-26-000077 |
| 2026-08-06 | 16:07 ET | [10-Q](/filings/0001867096-26-000065.md) | Quarterly report, period 2026-06-30 | 0001867096-26-000065 |
| 2026-08-06 | 07:12 ET | [8-K](/filings/0001867096-26-000063.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001867096-26-000063 |
| 2026-07-17 | 16:20 ET | [8-K](/filings/0001867096-26-000055.md) | 3.02 Unregistered sale of equity; 8.01 Other events | 0001867096-26-000055 |
| 2026-06-30 | 16:06 ET | [8-K](/filings/0001867096-26-000048.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001867096-26-000048 |
| 2026-06-11 | 07:16 ET | [8-K](/filings/0001867096-26-000045.md) | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001867096-26-000045 |
| 2026-06-05 | 16:14 ET | [8-K](/filings/0001867096-26-000034.md) | 5.07 Shareholder vote results | 0001867096-26-000034 |
| 2026-05-07 | 16:09 ET | [10-Q](/filings/0001867096-26-000030.md) | Quarterly report, period 2026-03-31 | 0001867096-26-000030 |
| 2026-05-07 | 07:15 ET | [8-K](/filings/0001867096-26-000027.md) | 2.02 Results of operations | 0001867096-26-000027 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001867096-26-000016.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/60b900d6-24f7-497a-96cc-2fe51fd5de4f)

## About the filer

- CIK: 1867096
- Tickers: XERS
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:37 ET. No prices; not investment advice.